OncLive Staff


FDA Granted Enzalutamide Priority Review to Treat Metastatic Hormone-Sensitive Prostate Cancer

August 22, 2019

The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), according to Astellas Pharma Inc. and Pfizer Inc., the codevelopers of the androgen receptor inhibitor.

FDA Approves Atezolizumab Combo for Frontline TNBC

March 08, 2019

The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)